by | Mar 14, 2024 | Lupus Foundation of America, News & Events
Because lupus is a chronic autoimmune disease that affects several organ systems, routine laboratory test measures are often abnormal. A new study looked to understand the relationship between certain indicators of systemic lupus erythematosus (SLE) disease activity...
by | Mar 8, 2024 | Lupus Foundation of America, News & Events
In people with systemic lupus erythematosus (SLE), a new study found an association between quality of life (QOL) and the ability to manage tough situations (also called psychological capital), post-traumatic growth, and social support. Lupus greatly impacts the QOL...
by | Mar 8, 2024 | Lupus Foundation of America, News & Events
A new study published in Lupus Science & Medicine discusses how machine learning (ML) opens new possibilities for studying lupus disease, from building predictive models, identifying new biomarkers, and developing techniques for understanding disease pathogenesis,...
by | Mar 4, 2024 | Lupus Foundation of America, News & Events
A new study looked at the possibility of a causal relationship between interleukin-18 (IL-18) cytokine and the risk of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE). Cytokines are proteins released by cells that have an effect on the...
by | Mar 1, 2024 | Lupus Foundation of America, News & Events
A new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) has been submitted to the U.S. Food and Drug Administration. ATA3219 is a CAR-T cell therapy. CAR-T cell...
by | Feb 26, 2024 | Lupus Foundation of America, News & Events
The Food & Drug Administration (FDA) has granted Fast Track designation to the investigational therapy, AlloNK® (also known as AB-101), to be used in combination with rituximab or obinutuzumab, as a possible treatment for lupus nephritis, (LN, lupus-related kidney...